Array Technologies(ARRY) Newsfile·2024-12-12 12:30Core Viewpoint - Medicus Pharma Ltd. has received Minor Use in Major Species (MUMS) designation from the FDA for its Doxorubicin-Containing Microneedle Array (D-MNA) patch aimed at treating external Squamous Cell Carcinoma (SCC) in horses, which positions the company for a potential first mover advantage in a niche market [2][3][4]. Company Overview - Medicus Pharma Ltd. is a biotech/life sciences company focused on advancing clinical development programs for novel therapeutics [9]. - The company’s D-MNA patch is a patent-protected, dissolvable transdermal patch that delivers doxorubicin directly to tumors [5]. Product Development - The FDA granted MUMS designation on December 9, 2024, allowing the company an extended 7-year exclusive marketing period post-approval [3][4]. - The D-MNA patch is designed to penetrate the skin, create microchannels, and release doxorubicin to target and eradicate cancer cells [5]. Market Opportunity - Squamous Cell Carcinoma (SCC) is a common skin tumor in horses, with an incidence rate of 2-3% among the estimated 6.6 to 7.25 million horses in the U.S. [6]. - The company aims to address an untapped market opportunity with a non-invasive treatment for equine SCC, potentially leading to a commercially viable product by 2026 [5]. Current Treatment Landscape - Current treatments for SCC in horses include surgical removal, cryotherapy, local chemotherapy injections, and topical chemotherapeutic drugs [7].